Welcome to LookChem.com Sign In|Join Free
  • or
(S)-2-benzyloxycarbonylamino-3-[4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)piperidin-1-yl]propionic acid is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

184107-25-3

Post Buying Request

184107-25-3 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

184107-25-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 184107-25-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,4,1,0 and 7 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 184107-25:
(8*1)+(7*8)+(6*4)+(5*1)+(4*0)+(3*7)+(2*2)+(1*5)=123
123 % 10 = 3
So 184107-25-3 is a valid CAS Registry Number.

184107-25-3Relevant academic research and scientific papers

Piperidine derivatives

-

, (2008/06/13)

A piperidine derivative of formula (1) or salts thereof: STR1 wherein R1 and R2 independently represent H or together represent O, R3 represents H, --R5 --COOR6, or --COOR6 (wherein R5

Synthesis and pharmacological evaluation of some amino-acid-containing cyproheptadine derivatives as dual antagonists of histamine H1- and leukotriene D4-receptors

Zhang,Van De Stolpe,Zuiderveld,Timmerman

, p. 95 - 102 (2007/10/03)

A novel series of cyproheptadine derivatives, in which an amino acid or a dipeptide moiety was introduced at the piperidine nitrogen, have been synthesized. The amino acid and dipeptide moieties were taken as part of leukotriene D4 (LTD4) pharmacophore. This modification reduced the H1-antihistamine activity (100-1000-fold) but elevated the anti-LTD4 activity (10-100-fold) of the compounds, as compared with cyproheptadine. As a result, some of the new compounds, especially the α-aminopropionic acid derivatives 4, are well-balanced dual antagonists of histamine and LTD4 with both activities at micromolar range. Radioligand binding studies have confirmed that the new compounds, but not cyproheptadine for LTD4, exert their action through competitive occupation of the receptors. One compound, (S)-2-benzyloxycarbonyl-amino-3-[4-(10,11-dihydro-5H- dibenzo[a,d]cyclohepten-5-yloxy)piperidin-1-yl]propionic acid (4c), was tested in an in vitro guinea-pig asthma model. It exhibits much more potent inhibition (IC50 = 1.5 μM) against antigen-induced contraction than either terfenadine or FPL55712, the reference drugs. As indicated by an ex vivo binding assay, the drug 4c does not readily pass the blood-brain barrier, and therefore is unlikely to cause sedating side-effects at a therapeutic dose.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 184107-25-3